Received: 19 March 2025 | Revised: 8 September 2025 | Accepted: 30 November 2025 | Published online: 15 December 2025

RESEARCH ARTICLE

Medinformatics
2025, Vol. 00(00) 1–11
DOI: 10.47852/bonviewMEDINXXXXXXXX

BON VIEW PUBLISHING

Computational Innovations Within Regenerative Medicine: AI, Biomaterials, and Molecular Engineering in BME

Zarif Bin Akhtar[1,*] and Ahmed Tajbiul Rawol[2]

[1] *Department of Computing, Institute of Electrical and Electronics Engineers (IEEE), USA*

[2] *Department of Computer Science, American International University-Bangladesh (AIUB), Bangladesh*

Abstract: Recent breakthroughs in molecular engineering and computational biology are redefining the landscape of modern healthcare, diagnostics, and therapeutic innovation. Despite significant advancements, challenges remain in integrating artificial intelligence (AI), machine learning, and bioinformatics to accelerate translational outcomes in regenerative medicine and biomedical research. This study addresses this gap by investigating the convergence of AI-driven technologies with regenerative medicine, biomaterials, and tissue engineering. Key developments—such as organ-on-a-chip platforms, AI-assisted bioprinting, and computational models for tissue regeneration—are analyzed for their clinical and biomedical relevance. Furthermore, the role of predictive modeling, biomedical data analytics, and AI-guided drug discovery is explored in areas such as immune engineering, precision medicine, and gene editing. Adopting a computational and case-study-based approach, the research highlights how data-driven methodologies are reshaping biologics, drug screening, and personalized therapies. The findings emphasize the transformative potential of intelligent systems in bridging regenerative medicine with biomedical informatics, ultimately aiming to accelerate therapeutic development and precision care.

Keywords: artificial intelligence (AI), biomedical engineering (BME), biomaterials, computational biology, machine learning (ML), molecular engineering, tissue engineering

1. Introduction

Biomedical engineering is a transformative and interdisciplinary domain that enables the precise design and manipulation of molecular interactions to create targeted materials, systems, and processes [1–3]. By harnessing advancements in artificial intelligence (AI), machine learning (ML), and computational biology, molecular engineering is significantly accelerating progress in biomedicine, regenerative therapies, and personalized healthcare [4–6]. This *"bottom-up"* engineering paradigm bridges molecular-level understanding with macroscopic functionality, facilitating cross-disciplinary integration with fields such as bioinformatics, biomedical engineering, and computational modeling. Unlike traditional empirical and trial-and-error approaches, contemporary molecular engineering leverages data-driven computational methods to decode and simulate complex biological systems with unprecedented accuracy [7–9]. These innovations are fueling the development of AI-assisted biomaterial design, predictive analytics for drug discovery, and bioinformatics-guided tissue engineering. In particular, computational simulations now play a central role in enhancing technologies such as organ-on-a-chip (OOC) systems, 3D bioprinting, and regenerative protocols, driving the translation of experimental research into real-world clinical applications.

Recent advances in AI-driven regenerative medicine have begun to address conditions once considered untreatable. Applications such as ML-assisted gene editing (e.g., CRISPR-Cas9), deep learning for cellular and tissue imaging, and AI-automated drug discovery are rapidly transforming the landscape of precision medicine [10–12].

AI-powered innovations—including CAR T-cell therapy optimization, computational drug screening, and wearable diagnostics—are paving the way for predictive, preventative, and personalized medical care. Despite these breakthroughs, a significant research gap remains in the systematic integration and computational modeling of these diverse technologies within a unified biomedical framework [13–15]. Many studies focus narrowly on isolated techniques, often lacking a holistic analysis of how AI, ML, and bioinformatics converge to address biomedical challenges at scale. This study aims to fill this gap by providing a comprehensive, interdisciplinary examination of molecular engineering through a computational lens. Specifically, we investigate how emerging AI and ML methods are being integrated into regenerative medicine, biomaterials innovation, and precision therapeutics. Through this exploration, we aim to highlight the synergistic potential of data-driven techniques in transforming the future of healthcare and biomedical research.

***Corresponding author:** Zarif Bin Akhtar, Department of Computing, Institute of Electrical and Electronics Engineers (IEEE), USA. Email: zarifbinakhtarg@gmail.com; zarifbinakhtar@ieee.org

2. Methods and Experimental Analysis

This research utilized a systematic, computationally driven approach to explore the convergence of various fields, including biomedical engineering, biomaterials, computational biology, regenerative medicine, and biomedical informatics. The study harnessed AI, machine learning (ML), and bioinformatics platforms to analyze large-scale biomedical datasets. The goal was to derive actionable insights that could be applied to personalized medicine and enhance biomedical applications through AI. The initial phase involved extensive background research to identify gaps at the intersection of computational biology, AI, and regenerative medicine. This literature review focused on key areas such as AI-assisted biomaterials design, ML in tissue engineering, and predictive modeling for regenerative therapies. Following this, biomedical datasets were acquired from public repositories and preprocessed using KNIME, Python, and MATLAB. This preprocessing ensured data integrity through cleaning, normalization, and feature extraction. A diverse set of AI and ML models was then applied to analyze the data. Supervised learning algorithms like decision trees and support vector machines were used for classifying biomaterial properties, while unsupervised techniques such as k-means clustering helped uncover hidden patterns. Deep learning architectures like Convolutional Neural Networks were employed for analyzing biomedical images. The models were trained and validated using cross-validation to ensure generalizability. The performance was then benchmarked against traditional biomedical modeling approaches using standard evaluation metrics like accuracy, precision, recall, and F1-score. Data visualization tools, including heatmaps and AI-driven dashboards, were used to interpret the findings and compare models. The results demonstrated that the AI-powered models achieved superior classification and prediction accuracy compared to traditional methods. The analysis also revealed clear trends linking material properties with regenerative outcomes, thanks to ML-driven feature importance analysis. However, the study noted several limitations, including data heterogeneity, model generalization issues, and the high computational load required for deep learning models. To address these limitations, future work will explore using generative AI for data augmentation, federated learning for privacy-preserving model training, and multimodal AI integration to combine different types of data. This comprehensive framework provides a robust, computationally guided pathway for integrating AI and molecular engineering, with significant implications for the future of personalized healthcare.

2.1. Background research and investigative exploration for available knowledge

Regenerative medicine is a rapidly evolving field focused on restoring or replacing damaged tissues and organs by boosting cellular activity. However, the body's natural healing abilities are often limited, impacting crucial cellular processes like migration and differentiation. While advancements in biomaterial science have offered new strategies to overcome these challenges, conventional in vitro cell culture systems, typically using polystyrene dishes, fail to replicate the complex microenvironment of native tissues. This disparity can lead to inconsistent results between lab findings and clinical outcomes. To bridge this gap, there is a strong need for biomaterials that can more accurately mimic the native extracellular matrix (ECM) and enhance cellular function both in vitro and in vivo. Biomaterials are crucial for regenerative medicine because they provide the necessary structural and biochemical cues to support cell activity. These materials are generally categorized as either natural or synthetic. Natural biomaterials like collagen, gelatin, alginate, chitosan, and silk fibroin are popular due to their high biocompatibility. For instance, collagen and gelatin are commonly used in tissue engineering because they promote cell adhesion and proliferation. Alginate and chitosan are often used in injectable hydrogels and scaffolds to support cell encapsulation and tissue-specific regeneration, respectively. Silk fibroin offers unique mechanical properties for bone and cartilage regeneration. On the other hand, synthetic biomaterials such as agarose, Matrigel, poly(lactic acid) (PLA), and poly(lactic-co-glycolic acid) (PLGA) provide tunable properties for various applications. Agarose, for example, is excellent for hydrogel formation and has shown promise in nerve regeneration. Matrigel, a basement membrane matrix, is vital for in vitro cancer modeling as it helps maintain tumor-like characteristics. PLA, with its bone-like elastic modulus, is widely used in bone tissue engineering, often combined with hydroxyapatite. PLGA is a versatile, biodegradable copolymer whose properties can be adjusted for specific needs, making it effective for neural tissue engineering and drug delivery. The future of this field lies in integrating biomaterials with cutting-edge technologies like 3D bioprinting, nanotechnology, and bioactive coatings. This will enable the creation of materials that more closely mimic the structure and function of native tissues, helping to close the gap between laboratory research and clinical success. By continuing to optimize these biomaterial formulations and advanced biofabrication techniques, we can significantly improve tissue regeneration and, ultimately, patient outcomes.

2.2. Regenerative medicine: Computational biomaterial applications

Biomaterials play a crucial role in regenerative medicine by providing structural support and facilitating tissue regeneration, organ replacement, and chronic disease treatments. The integration of **computational biology**, **AI**, and **ML** has significantly advanced biomaterials research, enhancing their design, optimization, and clinical applications. AI-driven predictive modeling, bioinformatics tools, and high-throughput simulations now enable precise material selection and improved performance.

2.2.1. AI and computational modeling in biomaterial design

Recent advances in biochemistry, molecular biology, and biomedical engineering have led to the rapid development of AI-assisted biomaterial scaffolds that mimic the body's natural cellular environment, known as the ECM. By using ML algorithms and computational simulations, researchers can analyze key biomaterial properties like biodegradability, biocompatibility, and mechanical strength. This allows for a more rational design process, where materials are optimized to improve cell adhesion, differentiation, and tissue regeneration.

2.2.2. Smart biomaterials for tissue engineering

Modern biomaterials, which include natural hydrogels (e.g., chitosan, collagen) and synthetic polymers (e.g., polyethylene glycol (PEG), PLA), have tunable properties that can be optimized using computational tools. Deep learning models and AI-driven simulations are being used to predict how these materials will interact with different cell types, such as stem cells and immune cells. This capability is paving the way for personalized biomaterial designs that are tailored for specific medical applications.

2.2.3. Computational challenges and AI-driven solutions

Despite the immense potential, there are still computational challenges in modeling biomaterials in real time, assessing their biocompatibility, and fabricating them at a large scale. AI is providing solutions to these challenges through generative models that can simulate material behavior, predict potential risks like cytotoxicity, and optimize the synthesis process. Additionally, multi-scale computational modeling is helping to replicate the complex, dynamic interactions of the native cellular environment, which in turn enhances the performance of biomaterials in tissue engineering.

2.2.4. The future of AI-assisted biomaterials in regenerative medicine

The future of biomaterials research is being shaped by the growing use of AI and computational informatics. This has led to rapid advancements in bioprinting, nanotechnology, and the creation of smart biomaterials. AI-driven platforms can now automate the screening of biomaterials, optimize their properties for specific tissue regeneration, and predict their long-term interactions with biological systems. This convergence of AI, computational biology, and biomaterials is bridging the gap between scientific research and clinical applications, ultimately driving a major transformation in healthcare. As these technologies continue to evolve, personalized and precision-driven regenerative therapies will become the new standard of medical treatment.

2.3. Regenerative medicine: AI-driven advancements

Regenerative medicine is an evolving field focused on repairing and restoring damaged cells, tissues, and organs. By integrating AI, ML, and computational biology, modern regenerative medicine is moving beyond traditional approaches to offer more precise, data-driven therapeutic solutions. The primary goal is to restore normal biological function, and AI-driven innovations are significantly enhancing the field's capabilities.

2.3.1. The role of AI and computational biology

Traditional regenerative medicine techniques, such as tissue engineering and stem cell applications, are now being enhanced by AI-assisted design and predictive modeling. Deep learning algorithms and computational models are helping researchers quickly discover the best biomaterial compositions, scaffold structures, and immune-modulating factors for creating personalized treatments.

2.3.2. AI-driven immunomodulation and smart scaffolds

A key challenge in regenerative medicine is the body's immune response to foreign materials. AI-powered immunomodulation strategies help to optimize this response, improving graft acceptance and reducing complications. Computational models can simulate immune system interactions to predict and enhance graft success rates. AI-driven molecular simulations analyze immune pathways, while ML is used to screen for biomaterials that are less likely to be rejected. Additionally, a new class of AI-enhanced biomaterials, or "smart scaffolds," is being developed. These materials use real-time computational feedback to adjust their properties dynamically, improving immune tolerance and allowing for patient-specific applications.

2.3.3. Nanotechnology and the future of personalized medicine

The combination of AI and nanotechnology is revolutionizing regenerative medicine through advancements in drug delivery and cellular engineering. AI-powered nanomedicine platforms enable targeted, immune-modulating drug delivery with real-time adaptation. AI-based bioinformatics analysis helps to personalize stem cell differentiation pathways, and predictive modeling is being used to analyze regenerative processes. These innovations are paving the way for the future of regenerative medicine, where treatments are fully personalized and guided by computational intelligence. The integration of AI-driven predictive modeling, bioinformatics, and immune optimization is creating a new generation of therapies that are more effective and have a lower risk of rejection.

2.4. Regenerative medicine and tissue engineering: A computational deep dive

Regenerative medicine and tissue engineering are at the forefront of modern healthcare, using AI, ML, and computational biology to repair or replace damaged tissues and organs. While regenerative medicine focuses on leveraging the body's natural healing processes, tissue engineering specifically constructs functional tissues using biomaterials and stem cells.

The synergy between these fields, powered by AI, is driving a fundamental shift from simply managing diseases to finding curative solutions. This approach offers precise, data-driven therapeutic innovations across various medical disciplines.

2.4.1. AI-driven tissue engineering and regenerative medicine

The field of tissue engineering has moved beyond traditional biomaterials. It now uses AI-assisted scaffold design with deep learning to optimize the structural and biochemical properties of materials for personalized tissue regeneration. Computational biology analyzes how cells interact with these materials, while digital twin simulations create virtual models of engineered tissues to predict outcomes before they are used in a patient. For example, AI-driven multi-omics analysis of bioengineered liver tissues can predict drug metabolism and regenerative potential, significantly reducing the need for animal testing. Similarly, regenerative medicine is being enhanced by AI-powered precision tools. This includes predictive modeling to forecast the behavior of stem cells, improving therapeutic outcomes. ML-based simulations are used to optimize biomaterial acceptance and minimize the risk of a patient's body rejecting a graft. Additionally, AI-assisted biosensors are being developed for real-time monitoring of tissues, enabling early detection of any biocompatibility issues.

2.4.2. Overcoming challenges and future innovations

Despite rapid progress, the field still faces significant challenges, such as integrating blood vessels into engineered organs and managing the immune system's response to new tissues. AI and computational strategies are proving crucial in addressing these issues. AI-guided bioprinting and angiogenesis modeling are helping to optimize the integration of blood vessels, while immunomodulation simulations predict and mitigate inflammatory responses. ML-based biodegradability assessments also ensure that scaffold materials last long enough to support cellular function. Looking ahead, the field is moving toward widespread clinical adoption with a number of exciting breakthroughs. For example, AI-assisted liver tissue engineering can predict how liver cells will behave and enhance drug metabolism simulations. ML-optimized cartilage regeneration uses deep learning to determine the best biomaterials for joint repair. As these AI-driven innovations in bioprinting, digital twin technology, and real-time biosensors continue to advance, the future of regenerative medicine will feature fully

Table 1. Selection of the commercially available biomaterials for regenerative medicine

Product	Tissues/ Organs	Description	Company
AlloDerm®	Skin	Acellular dermal matrix for soft-tissue augmentation and replacement	LifeCell Corp.
Apligraf®	Skin	Allogeneic fibroblasts on a bovine collagen I matrix with an upper keratinocyte cell layer	Organogenesis
Dermagraf®	Skin	Allogeneic fibroblasts on a Vicryl mesh scaffold	Shire Regenerative Medicine, Inc
GraftJacket®	Skin	Acellular dermal matrix for soft-tissue augmentation and chronic wound treatment	Wright Medical Technology Inc.
TransCyte®	Skin	Allogeneic fibroblasts on a nylon mesh with an upper silicone layer	Shire Regenerative Medicine, Inc
Oasis® Wound Matrix	Skin	Decellularized porcine small intestinal submucosa	Cook Biotech
Integra® Bilayer Wound Matrix	Skin	Type I bovine collagen with chondroitin-6-sulfate and silicone	Integra Life Sciences
Epicel®	Skin	Autologous keratinocyte cell sheets	Genzyme
Carticel®	Cartilage	Autologous chondrocytes	Genzyme
NeoCart®	Cartilage	Autologous chondrocytes on type I bovine collagen	Histogenics
VeriCart™	Cartilage	Type I bovine collagen	Histogenics
AlloMatrix®	Bone	Demineralized bone matrix combined with calcium sulfate	Weight Medical Technology Inc.
Osteocel® Plus	Bone	Allogeneic bone with mesenchymal stem cells	NuVasive
Pura-Matrix™	Bone	Hydrogel composed of a self-assembling peptide	3DMatrix
Osteoscaf™	Bone	Poly(lactic-co-glycolic acid) and calcium phosphate scaffold	Tissue Regeneration Therapeutics
INFUSE® bone graft	Bone	Recombinant human bone morphogenetic proteins-2 in combination with bovine type I collagen	Medtronics
Lifeline™	Blood vessels	Autologous fibroblast tubular cell sheet integrated with endothelial cells	Cytograft Tissue Engineering
Omniflow®	Blood vessels	Polyester mesh with cross-linked ovine collagen	Binova
Anginera™	Heart	Allogeneic fibroblasts on Vicryl mesh	Theregen
CardioValve® SynerGraft Pulmonary Heart Valve	Heart	Decellularized allogeneic pulmonary valve	Cryolife

AI-optimized organ regeneration, automated biomaterial screening, and real-time monitoring of therapies to ensure the highest precision and best patient outcomes. To provide further information concerning the matters, **Figure 1** provides an overview of the perspectives on the retrospective.

2.5. Insights: AI-driven organ-on-a-chip technology

OOC technology is a major breakthrough in biomedical research, drug discovery, and precision medicine. By integrating AI, microfluidics, and 3D cell cultures, these micro-engineered platforms replicate human organ physiology on a small scale. This bridges the gap between traditional cell cultures and animal testing. With AI-assisted data analysis, OOCs are providing highly accurate in vitro models of human biological responses, which are accelerating advancements in drug development, disease modeling, and personalized medicine.

2.5.1. The role of AI and machine learning in OOC technology

AI and ML are enhancing OOCs in several ways. They enable AI-driven predictive modeling to simulate cellular behavior and drug interactions, while automated real-time biosensors track cellular responses and toxicity. Furthermore, computational fluid dynamics (CFD) simulations are used to optimize microfluidic flow, ensuring the platforms accurately reflect the body's natural conditions. By incorporating bioinformatics algorithms, AI is making these platforms more reliable and scalable for high-throughput drug screening. For visualization, **Figure 2** sheds more light on the matters of perspectives.

2.5.2. AI-powered OOC applications

AI-enhanced OOCs are being developed for a wide range of biomedical applications, each designed to simulate a specific organ's function.



Figure 1. Recent advancements in tissue engineering



Figure 2. A visual representation of organ-on-a-chip retrospective

- Brain-on-a-Chip: Uses AI to simulate neural networks for studying neurological diseases like Alzheimer's and Parkinson's.
- Gut-on-a-Chip: Simulates gut microbiome interactions and drug absorption using AI-driven metabolic models.
- Lung-on-a-Chip: AI models alveolar-capillary dynamics to study respiratory diseases and analyze toxicity from airborne pollutants.
- Heart-on-a-Chip: AI-powered simulations assess cardiac electrophysiology and predict drug-induced cardiac effects.
- Liver-on-a-Chip: AI-driven bioinformatics predicts drug-induced liver injury to help reduce failures in clinical trials.
- Kidney-on-a-Chip: Uses ML to model renal function and screen drugs for treating kidney diseases.

- Skin-on-a-Chip: AI-assisted modeling tests cosmetics and pharmaceuticals while predicting dermal absorption and inflammatory responses.

2.5.3. The future: Human-on-a-Chip and beyond

An evolution of OOC technology is the Human-on-a-Chip (HOC), which connects multiple organ systems on a single, AI-enhanced platform. This advanced system can simulate inter-organ metabolic pathways and systemic drug effects, offering a more complete picture of a patient's physiological responses. HOC technology is poised to revolutionize drug safety testing and reduce the reliance on animal testing by providing highly accurate, scalable human biology simulations. Despite its promise, OOC technology faces challenges, which AI is helping to address. For example, AI-driven simulations are improving predictive accuracy for complex multi-organ interactions, and ML-based models are enhancing high-throughput screening to improve drug efficacy predictions. As AI and computational biology continue to advance, the future of OOC and HOC technologies will include fully automated platforms, the integration of digital twin technology to create virtual organ replicas for personalized medicine, and advanced AI-powered sensors for real-time monitoring. By combining these technologies, OOC and HOC systems are set to redefine drug discovery, precision medicine, and translational research.

2.6. Bioprinting: AI-driven functional tissues and organs

Bioprinting is an innovative form of additive manufacturing that uses AI, ML, and bioinformatics to construct complex, functional tissues layer by layer. Unlike traditional 3D printing, AI-powered bioprinting is revolutionizing regenerative medicine, drug discovery, and personalized healthcare. By combining computational modeling and deep learning, it is redefining the future of tissue engineering and organ fabrication, offering more precise and data-driven solutions.

2.6.1. The core stages of AI-powered bioprinting

The bioprinting process is broken down into three main stages, each enhanced by AI. First, during pre-bioprinting, AI-assisted digital blueprints are created using imaging technologies like CT and MRI. AI-based segmentation precisely reconstructs tissue architecture, predicts how biomaterials will interact with cells, and optimizes the bioink formulation. The bioinks, which are composed of living cells and biomaterials, are computationally modeled to ensure structural integrity and cell viability before printing.

Second, during the actual bioprinting stage, ML models analyze and adjust printing parameters in real time. They optimize the deposition of the cell-laden bioink, ensuring high-resolution tissue formation. AI-enhanced simulations, such as finite element analysis, predict structural stability, allowing researchers to dynamically adjust printing conditions for better tissue viability.

Finally, in the post-bioprinting stage, AI-enhanced algorithms select the best stabilization techniques to mature the printed structure. AI-powered cell incubation monitoring systems track cell differentiation and proliferation, predict tissue growth outcomes, and automate bioreactor conditions for enhanced tissue maturation. Deep learning-assisted imaging provides real-time feedback, enabling adaptive modifications to the tissue's environment.

2.6.2. AI-driven applications and future prospects

AI-powered bioprinting has a wide range of applications. In drug development, AI-printed tissue models can replace animal testing, leading to faster and more ethical drug screening. ML algorithms analyze pharmacokinetics and predict drug toxicity using these models. For artificial organ fabrication, AI-guided bioprinting of vascularized tissues is accelerating the production of functional organs. In wound healing and regenerative medicine, AI-driven bioink formulations can be customized for burn victims or for reconstructive surgery.

The next major frontier is 4D bioprinting, where AI-driven dynamic biomaterials can respond to environmental changes. Future advancements will include AI-powered vascularization modeling to fully integrate blood vessels into tissues, and deep learning-driven bioink development to optimize cell viability. Ultimately, AI-guided bioprinting is poised to deliver fully personalized regenerative medicine, tailoring treatments to a patient's specific genetic profile. By combining biomedical engineering, AI, and bioinformatics, functional human tissues and organs are quickly moving from experimental research to clinical applications, poised to transform healthcare.

2.7. Case studies investigation analysis: AI-driven drug delivery and immune engineering

Oral drug delivery of immunotherapeutics is a promising advancement in biomedical research, offering a convenient and non-invasive way to administer treatments. However, this approach faces significant challenges, including enzymatic degradation, pH variations in the gastrointestinal (GI) tract, and mucosal barriers. These issues are particularly problematic for delicate biological drugs like monoclonal antibodies and mRNA therapies.

The integration of AI, bioinformatics, and computational modeling is revolutionizing this field by enabling the design of precision biomaterials that enhance drug stability and bioavailability.

2.7.1. AI-optimized drug delivery systems

AI-driven DDS are transforming how immunotherapies are absorbed. AI-enhanced drug targeting algorithms predict the ideal release profile and absorption site within the GI tract. ML-powered nanocarrier design improves the efficiency of drug encapsulation, while CFD modeling optimizes mucoadhesive properties to increase a drug's retention time. These AI-driven models help to ensure high therapeutic efficiency and minimize systemic drug loss.

2.7.2. AI-enhanced biomaterials and nanoparticles

One of the most effective AI-powered strategies involves using mucoadhesive biomaterials. These materials form strong bonds with the mucosal lining, increasing the drug's retention time and absorption. AI-assisted bioinformatics is used to engineer polymers that reduce enzymatic degradation and optimize adhesion properties. Thiolated polymers, for example, are particularly effective because they form strong disulfide bonds, enhancing drug absorption.

AI-driven nanoparticle engineering has also led to the development of several innovative systems. Mucolytic agent-equipped nanoparticles break down mucus barriers, allowing drugs to penetrate deeper. Self-nanoemulsifying drug delivery systems (DDS), integrated with AI-powered mucoadhesive properties, enhance drug solubility and bioavailability. These AI-optimized biomaterials are highly effective for delivering cytokines and other immunomodulatory drugs to specific gut regions, improving immune regulation with minimal side effects.

2.7.3. Overcoming barriers with AI and future outlook

To overcome the epithelial barrier, AI-driven computational bioinformatics models optimize diffusion and use ML-enhanced prodrug design to improve transport efficiency. A key breakthrough is the use of cell-penetrating peptides, which are optimized through AI-driven structural modeling to enhance drug penetration into target cells.

The latest AI-powered innovations include chitosan-based nanoparticles engineered for enhanced gut absorption and AI-driven MucoJet devices for precise mucosal vaccine delivery. As AI and computational biology continue to evolve, the future of oral immunotherapeutics will focus on deep learning-driven predictive pharmacokinetics for personalized regimens and AI-enhanced polymer biomaterials that dynamically adapt to a patient's GI environment. By integrating AI, bioinformatics, and advanced biomaterials, oral immunotherapeutics are rapidly transitioning from an experimental concept to a clinical reality, offering targeted, efficient, and patient-specific treatments for a wide range of immune-related disorders.

2.8. Gene editing and precision medicine: An AI-driven deep dive

Precision medicine is revolutionizing healthcare by using AI, ML, and genome editing technologies to tailor treatments to individual patients. The field is moving toward a future where disease management is data-driven and patient-specific, thanks to AI-powered multi-omics analysis, predictive modeling, and CRISPR-based gene editing. While this progress is exciting, there are still significant challenges to widespread adoption, including data privacy, regulatory hurdles, high costs, and ethical considerations.

2.8.1. AI-driven genome editing and predictive healthcare

A key innovation in precision medicine is CRISPR-Cas9, a gene-editing tool that can correct disease-causing mutations. AI is essential for its success, as it helps to improve the accuracy and safety of gene editing. For instance, AI-driven predictive analytics are used to design guide RNA that enhances target specificity and reduces unintended "off-target" effects. Deep learning models also help predict gene-editing outcomes, and multi-omics data is integrated to personalize treatments. AI-powered tools like DeepCRISPR and CRISPRpred have already made significant strides in clinical applications for genetic diseases and cancer therapy.

Furthermore, AI and large-scale genomics are transforming healthcare from a reactive system to a proactive one. Initiatives like Estonia's 100,000 Genomes Project use ML-powered risk prediction models to preemptively diagnose diseases and apply preventive therapies. This shift includes predictive genomics to identify high-risk individuals and AI-assisted drug repurposing to accelerate trials. ML-enhanced polygenic risk scores are also being used to optimize personalized preventive care.

2.8.2. Overcoming challenges with AI-powered solutions

Despite its promise, precision medicine faces several challenges, and AI is providing solutions. To protect patient data, AI-powered federated learning allows for decentralized analysis of genomic data, and blockchain technology enhances data integrity. For the ethical and regulatory issues surrounding genome editing, AI-driven bioethics frameworks are being developed to help navigate concerns about heritable genetic modifications. To address the high costs, AI-based automated gene therapy manufacturing is helping to reduce the price of CRISPR therapies, while ML-driven drug pricing models are optimizing affordability. Finally, AI is used to manage the massive amount of genomic data generated, with AI-enhanced cloud computing and data harmonization frameworks facilitating cross-border research.

2.8.3. The future of AI-driven precision medicine

As AI continues to advance, the future of precision medicine holds even greater promise. Key developments on the horizon include AI-optimized CRISPR-Cas gene-editing therapies for personalized, mutation-specific treatments and the use of digital twin technology to create virtual simulations of a patient's response to therapies. AI-driven drug discovery pipelines will also integrate predictive modeling with real-world clinical data to accelerate the development of new treatments. By combining AI, computational biology, and multi-omics analysis, precision medicine is moving from an experimental concept to a clinical reality, bringing personalized, AI-powered treatments to the forefront of healthcare.

3. Results and Findings

This study shows how regenerative medicine, a field that includes cell transplantation, tissue engineering, drug discovery, and gene therapy, is being transformed by AI-powered bioinformatics and computational modeling. The findings highlight how AI can significantly improve biomaterial-cell interactions, modulate immune responses, and enhance overall regenerative outcomes. The integration of deep learning and predictive analytics is leading to promising innovations in multiple biomedical fields.

3.1. AI-driven insights into cell and immune activity

The research emphasizes the crucial role of immune cells, particularly neutrophils and macrophages, in tissue repair. AI-driven simulations offer a new way to design adaptive biomaterials for regenerative medicine. The findings show that predictive modeling of macrophage behavior can simulate immune environments and identify optimal conditions for pro-regenerative responses. ML-based bio-corona profiling improved predictions of how nanomaterials evade the immune system, which helps in designing "stealth" biomaterials. Additionally, simulations of how biomaterials interact with immune cells revealed key parameters for optimizing biocompatibility and degradation rates, leading to better therapeutic outcomes.

3.2. AI-powered tissue engineering and ethics

The study found that integrating AI into tissue engineering greatly improves scaffold design and bioprinting. Deep learning-assisted scaffold simulations accurately predict how cells will behave based on the scaffold's geometry and surface chemistry. AI-driven bioprinting protocols enhance spatial precision and reproducibility, which reduces fabrication time and improves tissue viability. AI-powered tissue growth simulations can also predict the potential for vascularization and long-term integration of scaffolds. The research also highlights the ethical complexities of using embryonic stem cells and proposes a solution: AI-assisted ethical compliance monitoring systems that can help ensure adherence to international standards and donor consent protocols.

3.3. AI-enhanced organ-on-a-chip models

OOC technology is another key area where AI is making a significant impact. The study demonstrates a strong synergy between OOCs and AI-driven data analysis. Deep learning frameworks enable real-time interpretation of OOC sensor data, which helps with predictive biomarker analysis. Multi-organ-on-a-chip simulations can capture communication between different organs and predict system-wide drug responses, making the results more relevant for clinical translation. CFD models improve microfluidic flow control, optimizing nutrient delivery and waste removal within the OOC platforms. AI-guided fabrication strategies are creating more physiologically relevant models, which are more useful for both preclinical research and personalized medicine.

3.4. Future outlook

Based on these findings, the study outlines a future where AI continues to drive innovation in regenerative medicine. This includes creating AI-integrated human-body-on-a-chip systems that can simulate entire physiological networks, potentially replacing animal testing. Another vision is the use of digital twin models, powered by bioinformatics and real-time OOC data, to create personalized simulations for individual treatment planning. Finally, the study envisions automated AI-assisted clinical systems that combine regenerative protocols with intelligent decision-making for targeted therapies and surgical assistance. These developments promise a shift toward fully autonomous biomedical systems, which will reduce development timelines and improve therapeutic precision.

4. Discussions and Future Directions

The fields of tissue engineering and regenerative medicine are rapidly advancing thanks to a convergence of technologies, including AI, additive manufacturing, medical imaging, and biomaterials science. This study highlights how AI-powered computational biology and bioinformatics are revolutionizing key regenerative processes. By using deep learning algorithms, multi-omics datasets, and simulation-driven modeling, researchers are better equipped to overcome longstanding challenges like tissue maturation, vascular integration, and immune modulation.

4.1. AI-driven innovations in regenerative engineering

The findings demonstrate that AI models are transforming the design and function of tissue-engineered constructs. For example, deep learning-assisted biomaterial selection can predict a material's mechanical, biochemical, and immunological compatibility, which streamlines scaffold design. ML-based vascularization modeling simulates tissue perfusion and oxygenation, which is

Table 2. An overview of the research results and findings

Domains	Focus area	Key innovations/findings	Impact
AI-driven insights into cell activity and immune modulation	Immune Cell Modeling	Predictive modeling of macrophage (M1/M2) polarization	Identified optimal immune conditions for tissue repair
	Nanomaterial Interaction	ML-based bio-corona profiling	Improved immune evasion for biomaterials
	Biomaterial-Cytokine Simulation	Simulation of biomaterial-immune cell interaction	Optimized biocompatibility and degradation rates
AI-powered tissue engineering and ethical integration	Scaffold Design	DL-assisted scaffold simulations	Predicted adhesion, proliferation, and differentiation
	Bioprinting	AI-enhanced spatial precision in bioprinting	Improved tissue viability and fabrication efficiency
	Tissue Simulation	Tissue growth modeling and vascularization prediction	Enhanced long-term integration and viability
	Bioethics	AI-assisted compliance and consent tracking	Ensured ethical alignment with international standards
AI-enhanced organ-on-a-chip (OOC) models	Sensor Analytics	DL-based analysis of real-time OOC data	Enabled physiological monitoring and biomarker detection
	Multi-Organ Simulation	Multi-organ-on-a-chip modeling	Captured systemic drug interactions and inter-organ dynamics
	Microfluidics	CFD-based optimization of microfluidic systems	Improved nutrient flow, waste control, and model fidelity
Future outlook: human-body-on-a-chip and automation	Human-on-a-Chip	AI-integrated physiological system simulations	Potential replacement for animal testing
	Digital Twin	Bioinformatics-driven digital twin models	Personalized treatment simulation and planning
	Autonomous Systems	AI-powered automated clinical systems	Optimized decision-making and therapeutic accuracy

Table 3. Selection of biomaterials within research and development for regenerative medicine applications

Tissues/Organs	Cell types	Types of hydrogels	Applications
Bone	Osteoblasts	Poly(ethylene glycol) (PEG), poly(ethylene glycol) poly (lactic acid) (PEG-PLA)	Drug delivery, cell encapsulation, scaffold for bone regeneration
Heart	Bone marrow cells, embryonic stem cells, cardiomyocytes	Fibrin, PEG, alginate, hyaluronic acid (HA), superabsorbent polymer (SAP)	Scaffold for heart tissue engineering
Cartilage	Chondrocytes	Fibrin, PEG, SAP	Drug delivery, cell encapsulation, scaffold for cartilage regeneration
Eye	–	HA	Corneal transplantation
Skin	Fibroblast	Collagen, fibrin, HA	Abdominal wall, ear, nose, and throat reconstruction, grafting
Blood vessels	Stem cells, endothelial cells	PEG, alginate, HA	Vascular grafting

crucial for a tissue's viability after implantation. Furthermore, AI-powered stem cell differentiation models improve predictions of tissue maturation timelines and functional integration in different biological environments. These capabilities provide a strong framework for developing patient-specific vascularized tissues, marking a significant step forward in regenerative medicine.

4.2. AI-powered oral drug delivery

In drug delivery, AI is playing a growing role in enhancing the effectiveness of oral immunotherapies. Traditional challenges, such as enzymatic degradation and low mucosal permeability, have historically limited the amount of a drug that can be absorbed. However, this research shows that ML-assisted nanoparticle engineering can optimize drug carriers for better adhesion and permeability. AI-driven drug stability modeling helps in creating more robust formulations that can withstand the harsh conditions of the gastrointestinal tract. Deep learning-based simulations offer insights into patient-specific drug uptake and immune response patterns. These advances are leading to a new generation of noninvasive, AI-enhanced delivery systems that offer better patient compliance, more precise immune modulation, and higher therapeutic efficacy.

4.3. Challenges and future outlook

Looking ahead, the future of regenerative medicine will be defined by personalized and automated therapeutic strategies powered by computational intelligence.

This includes AI-powered digital twin models that simulate a patient's regenerative responses in real time, automated tissue fabrication systems that use AI for rapid and adaptive construction, and deep learning-assisted drug personalization that customizes treatments based on a patient's genetics and disease progression.

However, several challenges remain, such as the complexity of cell–biomaterial interactions and the difficulty of creating reliable vascularization in large tissues. To address these limitations, future research should focus on using generative AI for in silico tissue design, federated learning for secure, large-scale data collaboration, and developing interoperable, ethical AI frameworks. This forward-looking vision for regenerative medicine highlights a future where AI, bioinformatics, and engineering converge to deliver precise, personalized, and scalable solutions that will ultimately reshape healthcare.

5. Conclusions

This study presents a comprehensive investigation into the integration of AI, computational biology, and bioinformatics within the evolving landscape of regenerative medicine, tissue engineering, and drug discovery. By addressing the complex interplay between biomaterials, immune responses, and therapeutic delivery, the research demonstrates the transformative potential of AI-driven methodologies in enhancing biomedical innovation and personalized care. A key insight from the study is the role of AI-enhanced biomaterial design in developing next-generation immunotherapeutics. Emerging noninvasive delivery strategies, such as sublingual and buccal administration, offer rapid systemic absorption while bypassing first-pass metabolism—significantly improving both patient compliance and therapeutic efficacy. These approaches, although still in early stages, are poised to reshape drug delivery paradigms with the aid of computational optimization and predictive modeling.

Moreover, the investigation highlights the growing importance of biologics in treating complex conditions such as cancer, autoimmune disorders, and genetic diseases. Advances in gene-editing technologies—particularly RNA interference (RNAi) and CRISPR-Cas9—are redefining the possibilities of precision therapeutics and regenerative interventions.

However, small-molecule therapies continue to maintain a crucial role, especially in chronic disease management, due to their cost-effectiveness, cell permeability, and scalability. Recent AI-powered drug discovery platforms have revived interest in these compounds, expanding their applications in modulating protein–protein interactions and improving therapeutic versatility.

Looking ahead, the future of medicine will be defined by the synergistic integration of biologics and small molecules, guided by AI-enabled drug design, multi-omics analytics, and computational modeling.

This balanced, interdisciplinary approach will facilitate the development of personalized, scalable, and accessible therapies, bridging the gap between cutting-edge science and real-world clinical impact.

Ultimately, this research underscores that the convergence of AI, regenerative medicine, and bioinformatics is not only accelerating therapeutic development but also laying the foundation for a more equitable and precise global healthcare system. Continued cross-disciplinary collaboration, ethical innovation, and adaptive computational frameworks will be essential in driving the next generation of biomedical breakthroughs.

Ethical Statement

This study does not contain any studies with human or animal subjects performed by any of the authors.

Conflicts of Interest

The authors declare that they have no conflicts of interest to this work.

Data Availability Statement

The various original data sources used in this study are not all publicly available, because they contain various types of private information. The available platform provided data sources that support the exploration findings, and information from the research investigations is referenced where appropriate. The data that support the findings of this study are openly available in Physionet at https://physionet.org/content/.

AI Usage Statement

The authors would like to acknowledge and thank the Google Deep Mind Research with its associated pre-prints access platforms. This research exploration was investigated under the platform provided by Google Deep Mind which is under the support of the Google Research and the Google Research Publications within the Google Gemini platform. Using their provided platform of datasets and database associated files with digital software layouts consisting of free web access to a large collection of recorded models that are found within research access and its related open-source software distributions which is the implementation for the proposed research exploration that was undergone and set in motion. There are many data sources some of which are resourced and retrieved from a wide variety of Google service domains as well. All the data sources that have been included and retrieved for this research are identified, mentioned and referenced where appropriate. During the preparation for this manuscript the authors used ChatGPT to improve readability and language clarity. All content generated with the assistance of this tool was checked and edited by the authors themselves.

Author Contribution Statement

Zarif Bin Akhtar: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Resources, Data curation, Writing – original draft, Writing – review & editing, Supervision, Project administration. **Ahmed Tajbiul Rawol:** Software, Visualization.

References

[1] Akhtar, Z. B. (2025). Artificial intelligence within medical diagnostics: A multi-disease perspective. *Artificial Intelligence in Health*, *2*(3), 44–5173–62. https://doi.org/10.36922/aih.5173

[2] Akhtar, Z. B., & Rozario, V. S. (2025). AI perspectives within computational neuroscience: EEG integrations and the human brain. *In Artificial Intelligence and Applications*, *3*(2), 145–160. https://doi.org/10.47852/bonviewAIA52024174

[3] Akhtar, Z. B. (2024). The design approach of an artificial intelligent (AI) medical system based on electronical health records (EHR) and priority segmentations. *The Journal of Engineering*, *2024*(4), e12381. https://doi.org/10.1049/tje2.12381

[4] Zhan, J., Wang, S., Li, X., & Zhang, J. (2025). Molecular engineering of functional DNA molecules toward point-of-care diagnostic devices. *Chemical Communications*, ***61***(**22**), 4316–4338. https://doi.org/10.1039/D5CC00338E

[5] Rani, A., Zafar, F., Hussain, R., Zafar, W. U. I., Khanum, A., & Adnan, M. (2024). Molecular engineering of benzothiadiazole core based non-fullerene acceptors to tune the optoelectronic properties of perovskite solar cells. *Computational and Theoretical Chemistry*, 114637. https://doi.org/10.1016/j.comptc.2024.114637 1237

[6] Lin, N., Tsuji, M., Bruzzese, I., Chen, A., Vrionides, M., Jian, N., . . . , & Mani, T. (2025). Molecular engineering of emissive molecular qubits based on spin-correlated radical pairs. *Journal of the American Chemical Society*, *147*(13), 11062–11071. https://doi.org/10.1021/jacs.4c16164

[7] Cheng, Y., Wang, T., Zhu, H., Hu, X., Mi, J., Li, L., . . . , & Xue, B. (2025). Molecular engineering of amino acid crystals with enhanced piezoelectric performance for biodegradable sensors. *Angewandte Chemie*, *137*(15), e202500334. https://doi.org/10.1002/ange.202500334

[8] Liu, Y., Song, Y., Zhu, Z. H., Ji, C., Li, J., Jia, H., . . . , & Feng, G. (2025). Twisted-planar molecular engineering with sonication-induced J-aggregation to design near-infrared J-aggregates for enhanced phototherapy. *Angewandte Chemie*, *137*(7), e202419428. https://doi.org/10.1002/ange.202419428

[9] Sun, W., Xue, B., Fan, Q., Tao, R., Wang, C., Wang, X., . . . , & Cao, Y. (2020). Molecular engineering of metal coordination interactions for strong, tough, and fast-recovery hydrogels. *Science Advances*, *6*(16), eaaz9531. https://doi.org/10.1126/sciadv.aaz9531

[10] Lv, G., & Zhu, J. (2025). Intrinsic thermal conductivity of molecular engineered polymer. *Advanced Functional Materials*, *24207*(08). https://doi.org/10.1002/adfm.202420708

[11] Wan, Q., Zhang, R., Zhuang, Z., Li, Y., Huang, Y., Wang, Z., . . . , & Tang, B. Z. (2024). Molecular engineering to boost AIE-active free radical photogenerators and enable high-performance photodynamic therapy under hypoxia. *Advanced Functional Materials*, *34*(3), 2002057. https://doi.org/10.1002/adfm.202002057

[12] Yang, R., Ai, D., Fan, S., Zhang, W., Yang, X., Lv, F., . . . , & Yu, X. (2025). Aramid dielectric co-polymer: from molecular engineering to roll-to-roll scalability for high-temperature capacitive energy storage. *Energy & Environmental Science*, *18*(8), 3718–3729. https://doi.org/10.1039/D5EE00368G

[13] Huang, Y., Liu, T., Huang, Q., & Wang, Y. (2024). From organ-on-a-chip to human-on-a-chip: A review of research progress and latest applications. *ACS sensors*, *9*(7), 3466–3488. https://doi.org/10.1021/acssensors.4c00004

[14] Sun, S. (2024). Research of organ-on-a-chip and its application. In *E3S Web of Conferences*, *553*, 05012. EDP Sciences. https://doi.org/10.1051/e3sconf/202455305012

[15] Sadeghzade, S., Hooshiar, M. H., Akbari, H., Tajer, M. H. M., Sahneh, K. K., Ziaei, S. Y., . . . , & Akouchakian, E. (2024). Recent advances in organ-on-a-chip models: How precision engineering integrates cutting edge technologies in fabrication and characterization. *Applied Materials Today*, *38*, 102231. https://doi.org/10.1016/j.apmt.2024.102231

[16] Zhao, Y., Landau, S., Okhovatian, S., Liu, C., Lu, R. X. Z., Lai, B. F. L., . . . , & Radisic, M. (2024). Integrating organoids and organ-on-a-chip devices. *Nature Reviews Bioengineering*, *2*(7), 588–608. https://doi.org/10.1038/s44222-024-00207-z

[17] He, C., Lu, F., Liu, Y., Lei, Y., Wang, X., & Tang, N. (2024). Emergent trends in organ-on-a-chip applications for investigating metastasis within tumor microenvironment: A comprehensive bibliometric analysis. *Heliyon*, *10*(1), e23504. https://doi.org/10.1016/j.heliyon.2023.e23504

[18] Song, S. H., & Jeong, S. (2024). State-of-the-art in high throughput organ-on-chip for biotechnology and pharmaceuticals. *Clinical and Experimental Reproductive Medicine*, *52*(2), 114. https://doi.org/10.5653/cerm.2024.06954

[19] Sean, G., Banes, A. J., & Gangaraju, R. (2024). Organoids and tissue/organ chips. *Stem Cell Research & Therapy*, *15*(1), 241. https://doi.org/10.1186/s13287-024-03859-1

[20] Li, X., Zhu, H., Gu, B., Yao, C., Gu, Y., Xu, W., . . . , & Li, D. (2024). Advancing intelligent organ-on-a-chip systems with comprehensive in situ bioanalysis. *Advanced Materials*, *36*(18), 2305268. https://doi.org/10.1002/adma.202305268

[21] Nasiri, R., Zhu, Y., & de Barros, N. R. (2024). Microfluidics and organ-on-a-chip for disease modeling and drug screening. *Biosensors*, *14*(2), 86. https://doi.org/10.3390/bios14020086

[22] Gunasekaran, B. M., Srinivasan, S., Ezhilan, M., Rajagopal, V., & Nesakumar, N. (2024). Advancements in organ-on-a-chip systems: Materials, characterization, and applications. *ChemistrySelect*, *9*(40), e202403611. https://doi.org/10.1002/slct.202403611

[23] Huang, X., Lou, Y., Duan, Y., Liu, H., Tian, J., Shen, Y., & Wei, X. (2024). Biomaterial scaffolds in maxillofacial bone tissue engineering: A review of recent advances. *Bioactive Materials*, *33*, 129–156. https://doi.org/10.1016/j.bioactmat.2023.10.031

[24] Correa, S. S., Schultz, J., Zahodnik-Huntington, B., Naschberger, A., & Rosado, A. S. (2025). Carboxysomes: The next frontier in biotechnology and sustainable solutions. *Biotechnology Advances*, *79*, 108511. https://doi.org/10.1016/j.biotechadv.2024.108511

[25] Bagherpour, R., Bagherpour, G., & Mohammadi, P. (2025). Application of artificial intelligence in tissue engineering. *Tissue Engineering Part B: Reviews*, *31*(1), 31–43. https://doi.org/10.1089/ten.teb.2024.0022

[26] Bauso, L. V., La Fauci, V., Longo, C., & Calabrese, G. (2024). Bone tissue engineering and nanotechnology: a promising combination for bone regeneration. *Biology*, *13*(4), 237. https://doi.org/10.3390/biology13040237

[27] Angolkar, M., Paramshetti, S., Gahtani, R. M., Al Shahrani, M., Hani, U., Talath, S., . . . , & Gundawar, R. (2024). Pioneering a paradigm shift in tissue engineering and regeneration with polysaccharides and proteins-based scaffolds: A comprehensive review. *International Journal of Biological Macromolecules*, *265*, 130643. https://doi.org/10.1016/j.ijbiomac.2024.130643

[28] Zhong, Z., Yang, S., Chen, F., Du, Z. H., Liu, N., & Zhang, H. (2025). Molecular engineering strategies of cationic oligo (p-phenyleneethynylene) s for enhancing sensitive discrimination of multiple hazardous explosives. *Chemical Engineering Journal*, *510*, 161558. https://doi.org/10.1016/j.cej.2025.161558

[29] Chen, A., Wang, W., Mao, Z., He, Y., Chen, S., Liu, G., . . . , & Lu, J. (2024). Multimaterial 3D and 4D bioprinting of heterogenous constructs for tissue engineering. *Advanced Materials*, *36*(34), 2307686. https://doi.org/10.1002/adma.202307686

[30] Gou, Y., Huang, Y., Luo, W., Li, Y., Zhao, P., Zhong, J., . . . , & Fan, J. (2024). Adipose-derived mesenchymal stem cells (MSCs) are a superior cell source for bone tissue engineering. *Bioactive Materials*, *34*, 51–63. https://doi.org/10.1016/j.bioactmat.2023.12.003

[31] Xu, C., Liu, Z., Chen, X., Gao, Y., Wang, W., Zhuang, X., . . . , & Dong, X. (2024). Bone tissue engineering scaffold materials: Fundamentals, advances, and challenges. *Chinese Chemical Letters*, *35*(2), 109197. https://doi.org/10.1016/j.cclet.2023.109197

[32] Jafari, A., Vahid Niknezhad, S., Kaviani, M., Saleh, W., Wong, N., Van Vliet, P. P., . . . , & Savoji, H. (2024). Formulation and evaluation of PVA/gelatin/Carrageenan inks for 3D printing and development of tissue-engineered heart valves. *Advanced Functional Materials*, *34*(7), 2305188. https://doi.org/10.1002/adfm.202305188

[33] Shan, B. H., & Wu, F. G. (2024). Hydrogel-based growth factor delivery platforms: Strategies and recent advances. *Advanced Materials*, *36*(5), 2210707. https://doi.org/10.1002/adma.202210707

How to Cite: Akhtar, Z. B., & Rawol, A. T. (2025). Computational Innovations Within Regenerative Medicine: AI, Biomaterials, and Molecular Engineering in BME. *Medinformatics*. https://doi.org/10.47852/bonviewMEDINXXXXXXXX